查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1477998

人造器官和医疗仿生市场：依产品类型、最终用户、地区 - 全球产业分析、规模、占有率、成长、趋势、预测，2024-2032 年

Artificial Vital Organs and Medical Bionics Market by Product Type, End-Users, and Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-20
出版日期: | 出版商: Persistence Market Research | 英文 306 Pages | 商品交期: 2-5个工作天内

价格
简介目录

这份研究报告对全球人造器官和医学仿生市场进行了详细的分析和解释。这份综合报告提供了有关主要市场趋势、市场驱动因素、课题和新兴趋势的宝贵见解。它详细概述了医疗保健行业的人造器官和医疗仿生学领域，并提供了独家数据和统计数据来预测 2024 年至 2032 年的市场成长轨迹。

关键见解

  • 人造器官与医疗仿生市场规模（2024 年）：548 亿美元
  • 预计市值（2032 年）：1,074 亿美元
  • 全球市场成长率（2024-2032 年复合年增长率）：8.7%

人造器官和医学仿生市场 - 报告范围：

人造器官和医疗仿生市场包括各种人造器官、仿生设备和再生医学解决方案，旨在替代或增强患者受损或失效的器官和组织的功能。该市场为医疗保健提供者、医疗设备製造商、生物技术公司以及患有器官衰竭、衰弱性损伤和慢性疾病的患者提供服务。人造器官和医学仿生技术包括人工心臟、仿生肢体、人工耳蜗、视网膜植入物和组织工程器官。生物医学工程、材料科学、再生医学的进步以及器官衰竭、创伤和与年龄相关的退化性疾病盛行率的增加推动了市场成长。

市场驱动因素：

全球人造器官和医学仿生学市场受益于几个关键的市场驱动因素。人造器官、植入物和组织工程的技术进步使得能够开发出更复杂、更实用的人造器官和仿生设备，并提高性能、耐用性和生物相容性。此外，对器官移植替代品、个人化医疗解决方案和患者特定植入物的需求不断增长正在推动市场扩张。人造器官和医学仿生学为末期器官衰竭和严重残疾的患者提供了挽救生命和增强生命的选择，提高了生活品质和长期结果。此外，支持性监管框架、政府资助措施和公私合作伙伴关係正在加速人造器官和医学仿生技术的创新和市场引入。

市场限制因素：

虽然人造器官和医疗仿生学市场有望显着成长，但它面临着技术可接受性、成本效益和病患可及性方面的课题。仿生设备、外科手术和术后护理的高昂成本可能会限制市场渗透和患者的承受能力，特别是在卫生预算有限的低收入和中等收入国家。此外，移植手术的复杂性和侵入性，以及併发症和设备故障的风险，给患者接受和临床医生采用人造器官和医学仿生技术带来了课题。此外，伦理考量、社会耻辱以及对人体增强和增强的文化态度可能会影响患者和社会对仿生植入物和再生医学治疗的接受程度。解决这些障碍需要医疗保健利益相关者、产业合作伙伴和政策制定者共同努力，促进人造器官和仿生医疗技术的可近性、可负担性和公平分配。

市场机会：

由于技术创新、以病人为中心的照护模式和市场扩张策略，人造器官和医疗仿生市场提供了巨大的成长机会。 3D 列印、奈米技术和生物电子医学等新兴趋势为个人化製造、小型化以及仿生植入物和组织工程结构的整合提供了新途径。生物混合器官、类器官和晶片器官平台的发展将进一步丰富药物筛选、疾病建模和个人化治疗所开发的生理和功能模型。此外，学术界、工业界和医疗保健提供者之间的策略合作将促进人造器官和医学仿生技术的转化研究、临床试验和商业化。此外，对病患教育、宣传和支援服务的重视将提高人们对仿生植入物和再生医学治疗的认识、接受度和依从性。

本报告涵盖的主要问题

  • 人造器官和医学仿生市场的复合年增长率是多少？
  • 人造器官和医疗仿生市场的主要国家有哪些？
  • 人造器官和医疗仿生学市场的领先细分市场有哪些？
  • 到 2032 年，人造器官和医疗仿生学市场的成长预测是多少？
  • 哪些地区的人造器官和医疗仿生市场潜力最大？

竞争资讯与业务策略：

全球人造器官和医疗仿生市场的领先公司，包括医疗器材製造商、生技公司和学术研究机构，都致力于创新、协作和市场拓展，以获得竞争优势。这些公司投资研发，开发针对特定临床适应症和患者群体的下一代人造器官、仿生设备和再生医学治疗方法。此外，与医疗保健提供者、患者倡导团体和监管机构的策略合作伙伴关係使公司能够验证产品的功效、安全性和市场适用性。此外，我们专注于以患者为中心的设计、使用者体验和基于结果的报销模式，在人造器官和医学仿生学的竞争格局中提高患者满意度和医疗保健价值。

公司主要简介

  • SynCardia Systems, LLC
  • BiVACOR
  • CARMAT
  • Cleveland Heart
  • Jarvik Heart
  • MyLVAD
  • Thoratec Corporation
  • Abbott Diabetes
  • Asahi Kasei Medical Co. Ltd.
  • Edwards Lifesciences Corporation

人造器官与医学仿生学市场研究细分：

依类型

  • 人造器官
  • 医学仿生学

依地区

  • 北美
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东/非洲

目录

第 1 章执行摘要

第二章市场概述

  • 市场范围/分类
  • 市场定义/范围/限制

第三章市场风险与趋势评估

  • 风险评估
    • COVID-19 危机及其对人工维生器官及医学仿生学需求的影响
    • 与过去的危机相比，新冠肺炎 (COVID-19) 影响基准
    • 对市场价值的影响
    • 主要国家的评价
    • 依主要细分市场进行评估
    • 针对供应商的行动要点和建议
  • 影响市场的主要趋势
  • 配方和产品开发的趋势

第四章市场背景与基本资料点

  • 全球人造器官与医学仿生市场
  • 人造器官与医学仿生学市场机会评估
    • 市场总规模
    • 可服务且可寻址的市场
    • 可服务且可用的市场
  • 市场情境预测
    • 乐观情况下的需求
    • 预期情况下的需求
    • 保守情境下的需求
  • 投资可行性分析
    • 投资成熟市场
      • 短期
      • 长期
    • 投资新兴市场
      • 短期
      • 长期
  • 预测因子 - 相关性和影响
    • 主要公司的历史成长
    • 全球人造器官和医学仿生市场的成长
    • 人工器官与医学仿生学引进率（依国家分列）
  • 市场动态
    • 市场驱动因素与影响评估
    • 主要市场课题与影响评估
    • 人造器官与医学仿生学的市场机会
    • 世界市场的重要趋势及其影响评估

第 5 章关键成功因素

  • 製造商专注于渗透率低但成长率高的市场
  • 押注该细分市场的高增量机会
  • 同业基准

第六章全球人造器官及医学仿生市场需求分析

  • 过去的市场分析（2019-2023）
  • 目前与未来的市场预测（2024-2032 年）
  • 年成长趋势分析

第七章全球人造器官及医学仿生市场价值分析

  • 过往市值分析（2019-2023 年）
  • 目前与未来的市值预测（2024-2032 年）
    • 年成长趋势分析
    • 绝对数量机会分析

第 8 章全球人造器官与医疗仿生市场分析：依类型

  • 简介/主要发现
  • 过去的市场规模分析：依类型（2019-2023 年）
  • 当前和未来的市场规模分析和预测：依类型划分（2024-2032 年）
    • 人工维生设备
    • 医学仿生学
  • 依类型划分的市场吸引力分析

第 9 章全球人造器官与医疗仿生市场分析：依地区

  • 简介
  • 过去的市场规模分析：依地区划分（2019-2023 年）
  • 目前与未来的市场规模分析与预测：依地区划分（2024-2032 年）
    • 北美
    • 拉丁美洲
    • 欧洲
    • 亚太地区
    • 中东和非洲 (MEA)
  • 依地区划分的市场吸引力分析

第十章北美人工器官及医学仿生市场分析

第十一章拉丁美洲人工器官与医学仿生市场分析

第十二章欧洲人造器官及医学仿生市场分析

第十三章亚太地区人工器官及医学仿生市场分析

第十四章中东及非洲人工器官及医学仿生市场分析

第十五章：主要国家人工器官及医学仿生市场分析

  • 简介
    • 主要国家市值比例分析
    • 世界与国家成长比较
  • 美国人造器官与医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 加拿大人造器官与医学仿生学市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 墨西哥人造器官与医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 巴西人造器官与医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 德国人造器官与医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 法国人造器官与医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 义大利人造器官与医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 比荷卢人造器官与医学仿生学市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 英国人造器官与医学仿生学市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 北欧国家人造器官与医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 中国人造器官及医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 日本人造器官与医学仿生学市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 韩国人造器官与医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 海湾合作委员会国家人造器官与医学仿生市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 南非人造器官与医学仿生学市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
  • 土耳其人造器官与医学仿生学市场分析
    • 依市场分类进行价值比率分析
    • 依市场分类划分的价值及分析与预测（2024-2032 年）
    • 国内竞争情势及企业集中度

第十六章市场结构分析

  • 依公司层级进行市场分析
  • 市场集中度
  • 主要公司市占率分析
  • 市场现况分析

第十七章竞争分析

  • 竞争对手仪表板
  • 竞争基准
  • 衝突详情
    • SynCardia Systems, LLC
    • BiVACOR
    • CARMAT
    • Cleveland Heart
    • Jarvik Heart
    • MyLVAD
    • Thoratec Corporation
    • Abbott Diabetes
    • Asahi Kasei Medical Co. Ltd.
    • Edwards Lifesciences Corporation

第 18 章假设与缩写

第十九章研究方法

简介目录
Product Code: PMRREP33106

Persistence Market Research, a renowned market research firm, has conducted an in-depth analysis of the global Artificial Vital Organs and Medical Bionics Market. This comprehensive report provides valuable insights into key market dynamics, growth drivers, challenges, and emerging trends. It offers a detailed overview of the artificial vital organs and medical bionics segment within the healthcare industry, presenting exclusive data and statistics projecting the market's growth trajectory from 2024 to 2032.

Key Insights:

  • Artificial Vital Organs and Medical Bionics Market Size (2024): USD54.8 Bn
  • Projected Market Value (2032): USD107.4 Bn
  • Global Market Growth Rate (CAGR 2024 to 2032):8.7%

Artificial Vital Organs and Medical Bionics Market - Report Scope:

The Artificial Vital Organs and Medical Bionics Market encompasses a wide range of artificial organs, bionic devices, and regenerative medicine solutions aimed at replacing or augmenting the function of damaged or failed organs and tissues in patients. This market serves healthcare providers, medical device manufacturers, biotechnology companies, and patients suffering from organ failure, debilitating injuries, or chronic diseases. Artificial vital organs and medical bionics technologies include artificial hearts, bionic limbs, cochlear implants, retinal prostheses, and tissue-engineered organs, among others. Market growth is driven by advancements in biomedical engineering, material science, and regenerative medicine, as well as increasing prevalence of organ failure, trauma injuries, and age-related degenerative disorders.

Market Growth Drivers:

The global Artificial Vital Organs and Medical Bionics Market benefits from several key growth drivers. Technological advancements in prosthetics, implants, and tissue engineering enable the development of more sophisticated and functional artificial organs and bionic devices with improved performance, durability, and biocompatibility. Moreover, increasing demand for organ transplantation alternatives, personalized medicine solutions, and patient-specific implants drives market expansion. Artificial vital organs and medical bionics offer life-saving and life-enhancing options for patients with end-stage organ failure or severe disabilities, improving their quality of life and long-term outcomes. Additionally, supportive regulatory frameworks, government funding initiatives, and public-private partnerships accelerate innovation and market adoption of artificial vital organs and medical bionics technologies.

Market Restraints:

Despite its significant growth prospects, the Artificial Vital Organs and Medical Bionics Market faces challenges related to technology acceptance, cost-effectiveness, and patient access. The high cost of bionic devices, surgical procedures, and postoperative care may limit market penetration and affordability for patients, particularly in low- and middle-income countries with constrained healthcare budgets. Moreover, the complexity and invasiveness of implantation procedures, as well as the risk of complications and device failures, pose challenges for patient acceptance and clinician adoption of artificial vital organs and medical bionics technologies. Furthermore, ethical considerations, social stigma, and cultural attitudes towards human enhancement and augmentation may influence patient and societal acceptance of bionic implants and regenerative medicine therapies. Addressing these barriers requires collaboration between healthcare stakeholders, industry partners, and policymakers to promote access, affordability, and equitable distribution of artificial vital organs and medical bionics technologies.

Market Opportunities:

The Artificial Vital Organs and Medical Bionics Market presents significant growth opportunities driven by technological innovations, patient-centered care models, and market expansion strategies. Emerging trends such as 3D printing, nanotechnology, and bioelectronic medicine offer new avenues for personalized fabrication, miniaturization, and integration of bionic implants and tissue-engineered constructs. The development of biohybrid organs, organoids, and organ-on-a-chip platforms enables more physiological and functional models for drug screening, disease modeling, and personalized therapy development. Moreover, strategic collaborations between academia, industry, and healthcare providers facilitate translational research, clinical trials, and commercialization of artificial vital organs and medical bionics technologies. Furthermore, emphasis on patient education, advocacy, and support services enhances awareness, acceptance, and adherence to bionic implants and regenerative medicine therapies.

Key Questions Answered in the Report:

  • What is the CAGR of the Artificial Vital Organs And Medical Bionics Market?
  • Which is the Leading Country in the Artificial Vital Organs And Medical Bionics Market?
  • Which Segment Leads in the Artificial Vital Organs And Medical Bionics Market by Type?
  • What is the Growth Estimated for the Artificial Vital Organs And Medical Bionics Market by 2032?
  • Which Region has the highest potential in the Artificial Vital Organs And Medical Bionics Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Artificial Vital Organs and Medical Bionics Market, including medical device manufacturers, biotechnology companies, and academic research institutions, focus on innovation, collaboration, and market expansion to gain a competitive edge. These companies invest in research and development to develop next-generation artificial organs, bionic devices, and regenerative medicine therapies tailored to specific clinical indications and patient populations. Moreover, strategic partnerships with healthcare providers, patient advocacy groups, and regulatory agencies enable companies to validate product efficacy, safety, and market readiness. Furthermore, emphasis on patient-centered design, user experience, and outcomes-based reimbursement models enhances patient satisfaction and healthcare value in the competitive landscape of artificial vital organs and medical bionics.

Key Companies Profiled:

  • SynCardia Systems, LLC
  • BiVACOR
  • CARMAT
  • Cleveland Heart
  • Jarvik Heart
  • MyLVAD
  • Thoratec Corporation
  • Abbott Diabetes
  • Asahi Kasei Medical Co. Ltd.
  • Edwards Lifesciences Corporation

Artificial Vital Organs and Medical Bionics Market Research Segmentation:

By Type

  • Artificial Vital Organs
  • Medical Bionics

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Summary of Statistics
  • 1.3. Key Market Characteristics & Attributes
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

  • 3.1. Risk Assessment
    • 3.1.1. COVID-19 Crisis and Impact on Artificial Vital Organs And Medical Bionics Demand
    • 3.1.2. COVID-19 Impact Benchmark with Previous Crisis
    • 3.1.3. Impact on Market Value (US$ Mn)
    • 3.1.4. Assessment by Key Countries
    • 3.1.5. Assessment by Key Market Segments
    • 3.1.6. Action Points and Recommendation for Suppliers
  • 3.2. Key Trends Impacting the Market
  • 3.3. Formulation and Product Development Trends

4. Market Background and Foundation Data Points

  • 4.1. Global Artificial Vital Organs And Medical Bionics Market (US$ Mn)
  • 4.2. Artificial Vital Organs And Medical Bionics Market Opportunity Assessment (US$ Mn)
    • 4.2.1. Total Available Market
    • 4.2.2. Serviceable Addressable Market
    • 4.2.3. Serviceable Obtainable Market
  • 4.3. Market Scenario Forecast
    • 4.3.1. Demand in optimistic Scenario
    • 4.3.2. Demand in Likely Scenario
    • 4.3.3. Demand in Conservative Scenario
  • 4.4. Investment Feasibility Analysis
    • 4.4.1. Investment in Established Markets
      • 4.4.1.1. In Short Term
      • 4.4.1.2. In Long Term
    • 4.4.2. Investment in Emerging Markets
      • 4.4.2.1. In Short Term
      • 4.4.2.2. In Long Term
  • 4.5. Forecast Factors - Relevance & Impact
    • 4.5.1. Top Companies Historical Growth
    • 4.5.2. Global Artificial Vital Organs And Medical Bionics Market Growth
    • 4.5.3. Artificial Vital Organs And Medical Bionics Adoption Rate, by Country
  • 4.6. Market Dynamics
    • 4.6.1. Market Driving Factors and Impact Assessment
    • 4.6.2. Prominent Market Challenges and Impact Assessment
    • 4.6.3. Artificial Vital Organs And Medical Bionics Market Opportunities
    • 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

  • 5.1. Manufacturers' Focus on Low Penetration High Growth Markets
  • 5.2. Banking on with Segments High Incremental Opportunity
  • 5.3. Peer Benchmarking

6. Global Artificial Vital Organs And Medical Bionics Market Demand Analysis 2019-2023 and Forecast, 2024-2032

  • 6.1. Historical Market Analysis, 2019-2023
  • 6.2. Current and Future Market Projections, 2024-2032
  • 6.3. Y-o-Y Growth Trend Analysis

7. Global Artificial Vital Organs And Medical Bionics Market Value Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032, By Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type, 2024-2032
    • 8.3.1. Artificial Vital Organs
    • 8.3.2. Medical Bionics
  • 8.4. Market Attractiveness Analysis By Type

9. Global Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032, By Region

  • 9.1. Introduction
  • 9.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 9.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2024-2032
    • 9.3.1. North America
    • 9.3.2. Latin America
    • 9.3.3. Europe
    • 9.3.4. Asia Pacific
    • 9.3.5. Middle East and Africa (MEA)
  • 9.4. Market Attractiveness Analysis By Region

10. North America Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 10.1. Introduction
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 10.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 10.4.1. By Country
      • 10.4.1.1. U.S.
      • 10.4.1.2. Canada
    • 10.4.2. By Type
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Country
    • 10.5.2. By Type

11. Latin America Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 11.1. Introduction
  • 11.2. Pricing Analysis
  • 11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 11.4.1. By Country
      • 11.4.1.1. Brazil
      • 11.4.1.2. Mexico
      • 11.4.1.3. Rest of Latin America
    • 11.4.2. By Type
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Country
    • 11.5.2. By Type

12. Europe Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 12.1. Introduction
  • 12.2. Pricing Analysis
  • 12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 12.4.1. By Country
      • 12.4.1.1. Germany
      • 12.4.1.2. France
      • 12.4.1.3. U.K.
      • 12.4.1.4. Italy
      • 12.4.1.5. Benelux
      • 12.4.1.6. Nordic Countries
      • 12.4.1.7. Rest of Europe
    • 12.4.2. By Type
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Country
    • 12.5.2. By Type

13. Asia Pacific Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Pricing Analysis
  • 13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 13.4.1. By Country
      • 13.4.1.1. China
      • 13.4.1.2. Japan
      • 13.4.1.3. South Korea
      • 13.4.1.4. Rest of Asia Pacific
    • 13.4.2. By Type
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Country
    • 13.5.2. By Type

14. Middle East and Africa Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Pricing Analysis
  • 14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 14.4.1. By Country
      • 14.4.1.1. GCC Countries
      • 14.4.1.2. South Africa
      • 14.4.1.3. Turkey
      • 14.4.1.4. Rest of Middle East and Africa
    • 14.4.2. By Type
  • 14.5. Market Attractiveness Analysis
    • 14.5.1. By Country
    • 14.5.2. By Type

15. Key Countries Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
    • 15.1.1. Market Value Proportion Analysis, By Key Countries
    • 15.1.2. Global Vs. Country Growth Comparison
  • 15.2. US Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.2.1. Value Proportion Analysis by Market Taxonomy
    • 15.2.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.2.2.1. By Type
  • 15.3. Canada Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.3.1. Value Proportion Analysis by Market Taxonomy
    • 15.3.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.3.2.1. By Type
  • 15.4. Mexico Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.4.1. Value Proportion Analysis by Market Taxonomy
    • 15.4.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.4.2.1. By Type
  • 15.5. Brazil Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.5.1. Value Proportion Analysis by Market Taxonomy
    • 15.5.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.5.2.1. By Type
  • 15.6. Germany Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.6.1. Value Proportion Analysis by Market Taxonomy
    • 15.6.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.6.2.1. By Type
  • 15.7. France Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.7.1. Value Proportion Analysis by Market Taxonomy
    • 15.7.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.7.2.1. By Type
  • 15.8. Italy Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.8.1. Value Proportion Analysis by Market Taxonomy
    • 15.8.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.8.2.1. By Type
  • 15.9. BENELUX Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.9.1. Value Proportion Analysis by Market Taxonomy
    • 15.9.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.9.2.1. By Type
  • 15.10. UK Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.10.1. Value Proportion Analysis by Market Taxonomy
    • 15.10.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.10.2.1. By Type
  • 15.11. Nordic Countries Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.11.1. Value Proportion Analysis by Market Taxonomy
    • 15.11.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.11.2.1. By Type
  • 15.12. China Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.12.1. Value Proportion Analysis by Market Taxonomy
    • 15.12.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.12.2.1. By Type
  • 15.13. Japan Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.13.1. Value Proportion Analysis by Market Taxonomy
    • 15.13.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.13.2.1. By Type
  • 15.14. South Korea Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.14.1. Value Proportion Analysis by Market Taxonomy
    • 15.14.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.14.2.1. By Type
  • 15.15. GCC Countries Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.15.1. Value Proportion Analysis by Market Taxonomy
    • 15.15.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.15.2.1. By Type
  • 15.16. South Africa Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.16.1. Value Proportion Analysis by Market Taxonomy
    • 15.16.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.16.2.1. By Type
  • 15.17. Turkey Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.17.1. Value Proportion Analysis by Market Taxonomy
    • 15.17.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.17.2.1. By Type
    • 15.17.3. Competition Landscape and Player Concentration in the Country

16. Market Structure Analysis

  • 16.1. Market Analysis by Tier of Companies
  • 16.2. Market Concentration
  • 16.3. Market Share Analysis of Top Players
  • 16.4. Market Presence Analysis
    • 16.4.1. By Regional footprint of Players
    • 16.4.2. Product footprint by Players

17. Competition Analysis

  • 17.1. Competition Dashboard
  • 17.2. Competition Benchmarking
  • 17.3. Competition Deep Dive
    • 17.3.1. SynCardia Systems, LLC
      • 17.3.1.1. Overview
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. Sales Footprint
      • 17.3.1.4. Strategy Overview
    • 17.3.2. BiVACOR
      • 17.3.2.1. Overview
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. Sales Footprint
      • 17.3.2.4. Strategy Overview
    • 17.3.3. CARMAT
      • 17.3.3.1. Overview
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. Sales Footprint
      • 17.3.3.4. Strategy Overview
    • 17.3.4. Cleveland Heart
      • 17.3.4.1. Overview
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. Sales Footprint
      • 17.3.4.4. Strategy Overview
    • 17.3.5. Jarvik Heart
      • 17.3.5.1. Overview
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. Sales Footprint
      • 17.3.5.4. Strategy Overview
    • 17.3.6. MyLVAD
      • 17.3.6.1. Overview
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. Sales Footprint
      • 17.3.6.4. Strategy Overview
    • 17.3.7. Thoratec Corporation
      • 17.3.7.1. Overview
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. Sales Footprint
      • 17.3.7.4. Strategy Overview
    • 17.3.8. Abbott Diabetes
      • 17.3.8.1. Overview
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. Sales Footprint
      • 17.3.8.4. Strategy Overview
    • 17.3.9. Asahi Kasei Medical Co. Ltd.
      • 17.3.9.1. Overview
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. Sales Footprint
      • 17.3.9.4. Strategy Overview
    • 17.3.10. Edwards Lifesciences Corporation
      • 17.3.10.1. Overview
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. Sales Footprint
      • 17.3.10.4. Strategy Overview

18. Assumptions and Acronyms Used

19. Research Methodology